AGO2 and urinary bladder carcinoma: As expected, knockdown of AGO2 led to a profound reduction in cell proliferation in a mutant HRASG12V/G12V-driven urinary bladder carcinoma cell line (T24) (32) and a HRASG13V/WT-driven acute lymphocytic leukemia cell line (Kasumi-2) (43) compared to a matched nontargeting control shRNA (Fig. 4A; Figure S3, Supplementary Material).